Caricamento...
The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy
Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared...
Salvato in:
| Pubblicato in: | Oncoimmunology |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Taylor & Francis
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5674967/ https://ncbi.nlm.nih.gov/pubmed/29147619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1358334 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|